Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 +1.49%69 EV-to-EBITDA is 9.23 as of Sep. 11, 2026, which is 14% below its 10-year median of 10.79. GuruFocus rates ROCO:7713 with a GF Score™ of 69/100 and a GF Value™ of NT$74.30 (Fairly Valued). The stock has 5 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 68.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Weleader Biomedical Co's enterprise value is NT$4,193 Mil.
Weleader Biomedical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$454 Mil. Therefore, Weleader Biomedical Co's EV-to-EBITDA for today is 9.23.
The historical rank and industry rank for Weleader Biomedical Co's EV-to-EBITDA or its related term are showing as below:
ROCO:7713'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.56 Med: 10.79 Max: 23.58
Current: 9.23
During the past 6 years, the highest EV-to-EBITDA of Weleader Biomedical Co was 23.58. The lowest was 8.56. And the median was 10.79.
ROCO:7713's EV-to-EBITDA is ranked better than 68.41% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.675
vs ROCO:7713: 9.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Weleader Biomedical Co (ROCO:7713) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Weleader Biomedical Co's PE Ratio (TTM) for today is calculated as:
Weleader Biomedical Co's share price for today is NT$75.00.
Weleader Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.165.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7713 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's EV-to-EBITDA falls into.
Weleader Biomedical Co's current Enterprise Value is NT$4,193 Mil.
Weleader Biomedical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$454 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a EV-to-EBITDA of 9.23 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Weleader Biomedical Co. This is 14% below median its historical median of 10.79. Over the past decade, Weleader Biomedical Co's EV-to-EBITDA has ranged from 8.56 to 23.58. According to the industry distribution chart, Weleader Biomedical Co ranks #163 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 31.6%.
Is Weleader Biomedical Co's EV-to-EBITDA too high?
Weleader Biomedical Co's current EV-to-EBITDA of 9.23 is 14% below median its 10-year median of 10.79. Over the past 10 years, this metric has ranged from a low of 8.56 to a high of 23.58. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.68. Weleader Biomedical Co's value of 9.23 is 32.5% below this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #163 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #163 out of 516 companies for EV-to-EBITDA. This puts Weleader Biomedical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.68. Weleader Biomedical Co's value of 9.23 is 32.5% below this benchmark. Historically, Weleader Biomedical Co's own EV-to-EBITDA has ranged from 8.56 to 23.58 over the past decade. While the company's 10-year median is 10.79 vs. the industry median of 13.68, Weleader Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.68, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current EV-to-EBITDA of 9.23 is 32.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Weleader Biomedical Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current EV-to-EBITDA is 9.23, which is 14% below median its own 10-year median of 10.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.30, compared to a current price of NT$75.00 — trading 0.9% above its estimated fair value. The current EV-to-EBITDA is 9.23, which is 14% below median its 10-year median of 10.79 and 32.5% below the Medical Devices & Instruments industry median of 13.68. Weleader Biomedical Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current EV-to-EBITDA is 9.23 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?
Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be overvalued.
The current stock price of NT$75.00 is trading 0.9% above its estimated GF Value™ of NT$74.30.
GuruFocus considers Weleader Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:7713:
EV-to-EBITDA: 9.23 (14% below median its 10-year median of 10.79)
GF Value™: NT$74.30 vs. price of NT$75.00 (0.9% above fair value)
Industry Position: 32.5% below the Medical Devices & Instruments median (#163 of 516)
No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
69GF Score
Get the complete analysis for ROCO:7713
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
